FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Alexander Spira; Byoung Chul Cho; Enriqueta Felip; Edward B. Garon; Koichi Goto; Melissa Johnson; Natasha Leighl; Antonio Passaro; David Planchard; Sanjay Popat; James Chih Hsin Yang; Xiaoqian Lu; Yong Jiang; Jack Huang; Morgan Lam; Marcin Kowanetz; Shirley Wang; John Le; Jerry Y. Hsu; Cai Cun Zhou

doi:10.1016/j.lungcan.2024.108066

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Koichi Goto, Melissa Johnson, Natasha Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih Hsin Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John Le, Jerry Y. Hsu, Cai Cun Zhou

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

langue originale	Anglais
Numéro d'article	108066
journal	Lung Cancer
Volume	199
Les DOIs	https://doi.org/10.1016/j.lungcan.2024.108066
état	Publié - 1 janv. 2025

Accès au document

10.1016/j.lungcan.2024.108066

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Spira, A., Cho, B. C., Felip, E., Garon, E. B., Goto, K., Johnson, M., Leighl, N., Passaro, A., Planchard, D., Popat, S., Yang, J. C. H., Lu, X., Jiang, Y., Huang, J., Lam, M., Kowanetz, M., Wang, S., Le, J., Hsu, J. Y., & Zhou, C. C. (2025). FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer, 199, Article 108066. https://doi.org/10.1016/j.lungcan.2024.108066

@article{85f9e0957fbd47dab7cfc239fd133a67,

title = "FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)",

keywords = "Advanced, EGFR, EGFR-TKI, Ex20ins, Exon 20 insertions, Firmonertinib, Furmonertinib, Metastatic",

author = "Alexander Spira and Cho, {Byoung Chul} and Enriqueta Felip and Garon, {Edward B.} and Koichi Goto and Melissa Johnson and Natasha Leighl and Antonio Passaro and David Planchard and Sanjay Popat and Yang, {James Chih Hsin} and Xiaoqian Lu and Yong Jiang and Jack Huang and Morgan Lam and Marcin Kowanetz and Shirley Wang and John Le and Hsu, {Jerry Y.} and Zhou, {Cai Cun}",

year = "2025",

month = jan,

day = "1",

doi = "10.1016/j.lungcan.2024.108066",

language = "English",

volume = "199",

journal = "Lung Cancer",

issn = "0169-5002",

}

Spira, A, Cho, BC, Felip, E, Garon, EB, Goto, K, Johnson, M, Leighl, N, Passaro, A, Planchard, D, Popat, S, Yang, JCH, Lu, X, Jiang, Y, Huang, J, Lam, M, Kowanetz, M, Wang, S, Le, J, Hsu, JY & Zhou, CC 2025, 'FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)', Lung Cancer, VOL. 199, 108066. https://doi.org/10.1016/j.lungcan.2024.108066

TY - JOUR

T1 - FURVENT

T2 - Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

AU - Spira, Alexander

AU - Cho, Byoung Chul

AU - Felip, Enriqueta

AU - Garon, Edward B.

AU - Goto, Koichi

AU - Johnson, Melissa

AU - Leighl, Natasha

AU - Passaro, Antonio

AU - Planchard, David

AU - Popat, Sanjay

AU - Yang, James Chih Hsin

AU - Lu, Xiaoqian

AU - Jiang, Yong

AU - Huang, Jack

AU - Lam, Morgan

AU - Kowanetz, Marcin

AU - Wang, Shirley

AU - Le, John

AU - Hsu, Jerry Y.

AU - Zhou, Cai Cun

PY - 2025/1/1

Y1 - 2025/1/1

KW - Advanced

KW - EGFR

KW - EGFR-TKI

KW - Ex20ins

KW - Exon 20 insertions

KW - Firmonertinib

KW - Furmonertinib

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=85214025163&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2024.108066

DO - 10.1016/j.lungcan.2024.108066

M3 - Review article

AN - SCOPUS:85214025163

SN - 0169-5002

VL - 199

JO - Lung Cancer

JF - Lung Cancer

M1 - 108066

ER -